From: Evaluation of ARK5 and SIRT3 expression in renal cell carcinoma and their clinical significance
 | ARK5- H -score Mean ± SD | SIRT3- H -score Mean ± SD | Test | P value |
---|---|---|---|---|
Gender | ||||
 Male | 163.7 ± 57.7 | 128.6 ± 83.2 | Mann–Whitney | P1 = 0.85 P2 = 0.82 |
 Female | 165.7 ± 53.2 | 144.5 ± 78.9 | ||
Histological type clear | 154.8 ± 66.3 | 128.4 ± 88.4 | Kruskal–Wallis | P1 = 0.11 P2 = 0.13 |
 Papillary | 160.0 ± 30.0 | 77.1 ± 77.8 | ||
 Chromophobe | 191.6 ± 31.8 | 172.5 ± 39.2 | ||
 Others | 133.3 ± 28.8 | 133.3 ± 115.9 | ||
Tumour grade | ||||
 1 | 118.0 ± 69.9 | 114.67 ± 74.7 | Kruskal–Wallis | P1 = 0.01* P2 = 0.037* |
 2 | 175.2 ± 38.68 | 115.7 ± 88.8 | ||
 3 | 187.86 ± 31.67 | 162.86 ± 64.97 | ||
 4 | 182.5 ± 53.18 | 172.5 ± 83.96 | ||
Apoptosis | 164.48 ± 55.6 | 134.66 ± 81.2 | Pearson | P1 = 0.035 P2 = 0.016* |
Mitosis | 164.5 ± 55.6 | 134.66 ± 81.2 | Pearson | P1 = 0.001** P2 = 0.002* |
Tumour Extent | ||||
 1 | 130.5 ± 67.2 | 92.5 ± 79.5 | Kruskal–Wallis | P1 = 0.004* P2 = 0.001** |
 2 | 177.1 ± 37.0 | 133.8 ± 72.1 | ||
 3 | 182.0 ± 37.8 | 187.0 ± 67.8 | ||
 4 | 240.0 ± 21.2 | 230.0 ± 42.4 | ||
Stage | ||||
 I | 130.5 ± 67.2 | 92.5 ± 79.5 | Kruskal–Wallis | P1 = 0.003* P2 = 0.001** |
 II | 174.0 ± 35.0 | 132.5 ± 73.7 | ||
 III | 185.6 ± 39.3 | 176.9 ± 65.7 | ||
 IV | 240.0 ± 21.2 | 240.0 ± 42.4 | ||
Response to chemotherapy | ||||
 No | 200.4 ± 23.5 | 183.1 ± 62.1 | Kruskal–Wallis | P1 = 0.013* P2 = 0.037* |
 Partial | 177.4 ± 40.9 | 123.2 ± 82.5 | ||
 Complete | 141.7 ± 43.1 | 53.3 ± 88.5 | ||
ARK5 and SIRT3 | 164.5 ± 55.651 | 134.6 ± 81.2 | Pearson correlation (R) 0.342 | 0.009* |